Contributions of genetically modified mouse models to understanding the physiology and pathophysiology of the 25-hydroxyvitamin D-1-alpha hydroxylase enzyme (1α(OH)ase) and the vitamin d receptor (VDR)

Vitamin D

Volumn , Issue , 2011, Pages 583-603

  Hendy, Geoffrey N ^a   Kremer, Richard ^a   Goltzman, David ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84870814684     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381978-9.10033-2     Document Type: Chapter

References (218)

1. Jones G., Strugnell S.A., DeLuca H.F. Current understanding of the molecular actions of vitamin D. Physiol. Rev. 1998, 78:1193-1231.
2. Brenza H.L., DeLuca H.F. Regulation of 25-hydroxyvitamin D3 1alpha-hydroxylase gene expression by parathyroid hormone and 1,25-dihydroxyvitamin D3. Arch. Biochem. Biophys. 2000, 381:143-152.
3. Bai X., Miao D., Li J., Goltzman D., Karaplis A.C. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 2004, 145:5269-5279.
4. 3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses. J. Clin. Endocrinol. Metab. 1997, 82:2222-2232.
5. Adams J.S., Chen H., Chun R., Gacad M.A., Encinas C., Ren S., et al. Response element binding proteins and intracellular vitamin D binding proteins: novel regulators of vitamin D trafficking, action and metabolism. J. Steroid Biochem. Mol. Biol. 2004, 89-90:461-465.
6. Haussler M.R., Haussler C.A., Bartik L., Whitfield G.K., Hsieh J.C., Slater S., et al. Vitamin D receptor: molecular signaling and actions of nutritional ligands in disease prevention. Nutr. Rev. 2008, 66(10 Suppl. 2):S98-S112.
7. Glorieux F.H., St-Arnaud R. Molecular cloning of (25-OH D)-1 alpha-hydroxylase: an approach to the understanding of vitamin D pseudo-deficiency. Recent Prog. Horm. Res. 1998, 53:341-349.
8. Liberman U.A. Vitamin D-resistant diseases. J. Bone Miner. Res. 2007, 22(Suppl. 2):V105-V107.
9. Panda D.K., Miao D., Tremblay M.L., Sirois J., Farookhi R., Hendy G.N., et al. Targeted ablation of the 25-hydroxyvitamin D 1alpha-hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc. Natl. Acad. Sci. USA 2001, 98:7498-7503.
10. Dardenne O., Prud'homme J., Arabian A., Glorieux F.H., St-Arnaud R. Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. Endocrinology 2001, 142:3135-3141.
11. Yoshizawa T., Handa Y., Uematsu Y., Takeda S., Sekine K., Yoshihara Y., et al. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat. Genet. 1997, 16:391-396.
12. Li Y.C., Pirro A.E., Amling M., Delling G., Baron R., Bronson R., et al. Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proc. Natl. Acad. Sci. USA 1997, 94:9831-9835.
13. Van Cromphaut S.J., Dewerchin M., Hoenderop J.G., Stockmans I., Van Herck E., Kato S., et al. Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects. Proc. Natl. Acad. Sci. USA 2001, 98:13324-13329.
14. Erben R.G., Soegiarto D., Weber K., Zeitz U., Lieberherr M., Gniadecki R., et al. Deletion of deoxyribonucleic acid binding domain of the vitamin D receptor abrogates genomic and nongenomic functions of vitamin D. Mol. Endocrinol. 2002, 16:1524-1537.
15. Panda D.K., Miao D., Bolivar I., Li J., Huo R., Hendy G.N., et al. Inactivation of the 25-hydroxyvitamin D 1α-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J. Biol. Chem. 2004, 279:16754-16766.
16. Hoenderop J.G., Hartog A., Stuiver M., Doucet A., Willems P.H., Bindels R.J. Localization of the epithelial Ca(2+) channel on rabbit kidney and intestine. J. Am. Soc. Nephrol. 2000, 11:1171-1178.
17. Hoenderop J.G., Nilius B., Bindels R.J. Calcium absorption across epithelia. Physiol. Rev. 2005, 85:373-422.
18. Van Abel M., Hoenderop J.G., van der Kemp A.W., van Leeuwen J.P., Bindels R.J. Regulation of the epithelial Ca2+ channels in small intestine as studied by quantitative mRNA detection. Am. J. Physiol. Gastrointest. Liver Physiol. 2003, 285:G78-G85.
19. Song Y., Peng X., Porta A., Takanaga H., Peng J.B., Hediger M.A., et al. Calcium transporter 1 and epithelial calcium channel messenger ribonucleic acid are differentially regulated by 1, 25 dihydroxyvitamin D3 in the intestine and kidney of mice. Endocrinology 2003, 144:3885-3894.
20. Song Y., Kato S., Fleet J.C. Vitamin D receptor (VDR) knockout mice reveal VDR-independent regulation of intestinal calcium absorption and ECaC2 and calbindin D9k mRNA. J. Nutr. 2003, 133:374-380.
21. Dostal L.A., Toverud S.U. Effect of vitamin D 3 on duodenal calcium absorption in vivo during early development. Am. J. Physiol. 1984, 246:G528-G534.
22. Halloran B.P., DeLuca H.F. Appearance of the intestinal cytosolic receptor for 1,25-dihydroxyvitamin D3 during neonatal development in the rat. J. Biol. Chem. 1981, 256:7338-7342.
23. Dardenne O., Prudhomme J., Hacking S.A., Glorieux F.H. Rescue of the pseudo-Vitamin D deficiency rickets phenotype of CYP27B1-deficient mice by treatment with 1,25-dihydroxyVitamin D3: biochemical, histomorphometric, and biomechanical analyses. J. Bone Miner. Res. 2003, 18:637-643.
24. Li Y.C., Pirro A.E., Demay M.B. Analysis of vitamin D-dependent calcium-binding proteion messenger ribonucleic acid expression in mice lacking the vitamin D receptor. Endocrinology 1998, 139:847-851.
25. Bolt M.J., Cao L.P., Kong J., Sitrin M.D., Li Y.C. Vitamin D receptor is required for dietary calcium-induced repression of calbindin-D9k expression in mice. J. Nutr. Biochem. 2005, 16:286-290.
26. Bianco S.D., Peng J.B., Takangar H., Suzuki Y., Crescenzi A., Kos C.H., et al. Marked disturbance of calcium homeostasis in mice with targeted disruption of the Trpv6 calcium channel gene. J. Bone Miner. Res. 2007, 22:274-285.
27. Benn N.S., Ajibade D., Porta A., Dhawan P., Hediger M., Peng J.B., et al. Active intestinal calcium transport in the absence of transient receptor potential vanilloid type 6 and calbindin-D9k. Endocrinology 2008, 149:3196-3205.
28. Kutuzova G.D., Akhter S., Christakos S., Vanhooke J., Kimmel-Jehan C., DeLuca H.F. CalbindinD(9k) knockout mice are indistinguishable from wild-type mice in phenotype and calcium level. Proc. Natl. Acad Sci. USA 2006, 103:12377-12381.
29. Lee G.S., Lee K.Y., Choi K.C., Ryu Y.H., Paik S.G., Oh G.T., et al. Phenotype of a calbindin-D9k gene knockout is compensated for by the induction of other calcium transporter genes in a mouse model. J. Bone Miner. Res. 2007, 22:1968-1978.
30. Fujita H., Sugimoto K., Inatomi S., Maeda T., Osani M., Uchiyama Y., et al. Tight junction proteins claudin-2 and -12 are critical for vitamin D-dependent Ca2+ absorption between enterocytes. Mol. Biol. Cell 2008, 19:1912-1921.
31. Li Y.C., Bolt M.J., Cao L.P., Sitrin M.D. Effects of vitamin D receptor inactivation on the expression of the calbindins and calcium metabolism. Am. J. Physiol. Endocrinol. Metab. 2001, 281:E558-E564.
32. Hoenderop J.G., Dardenne O., van Abel M., van der Kemp A.W., van Os C.H., St Arnaud R., et al. Modulation of renal Ca2+ transport protein genes by dietary Ca2+ and 1,25-dihydroxyvitamin D3 in 25-hydroxyvitamin D3-1α-hydroxylase knockout mice. FASEB J. 2002, 16:1398-1406.
33. Hoenderop J.G., van Leeuwen J.P., Van der Eerden B.C., Kersten F.F., van der Kemp A.W., Merillat A.M., et al. Renal Ca2+ wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5 knockout mice. J. Clin. Invest. 2003, 112:1906-1914.
34. Renkema K.Y., Nijenhuis T., van der Eerden B.C., van der Kemp A.W., Weinans H., van Leeuwen J.P., et al. Hypervitaminosis D mediates compensatory Ca2+ hyperabsorption in TRPV5 knockout mice. J. Am. Soc. Nephrol. 2005, 16:3188-3195.
35. Airaksinen M.S., Eilers J., Garaschuk O., Thoenen H., Konnerth A., Meyer M. Ataxia and altered dendritic calcium signaling in mice carrying a targeted null mutation of the calbindin D28k gene. Proc. Natl. Acad. Sci. USA 1997, 94:1488-1493.
36. Margolis D.S., Kim D., Szivek J.A., Lai L.W., Lien Y.H. Functionally improved bone in calbindin-D28k knockout mice. Bone 2006, 39:477-484.
37. Sooy K., Kohut J., Christakos S. The role of calbindin and 1,25-dihydroxyvitamin D3 in the kidney. Curr. Opin. Nephrol. Hypertens. 2000, 9:341-347.
38. Zheng W., Xie Y., Li G., Kong J., Feng J.Q., Li Y.C. Critical role of calbindin-D28k in calcium homeostasis revealed by mice lacking both vitamin D receptor and calbindin-D29k. J. Biol. Chem. 2004, 279:52406-52413.
39. Gkika D., Hsu Y.J., van der Kemp A.W., Christakos S., Bindels R.J., Hoenderop J.G. Critical role of the epithelial Ca2+ channel TRPV5 in active Ca2+ reabsorption as revealed by TRPV5/calbindin-D28k knockout mice. J. Am. Soc. Nephrol. 2006, 17:3020-3027.
40. Koushik S.V., Wang J., Rogers R., Moskophidis D., Lambert N.A., Creazzo T.L., et al. Targeted inactivation of the sodium-calcium exchanger (Ncx1) results in the lack of a heartbeat and abnormal myofibrillar organization. FASEB J. 2001, 15:1209-1211.
41. Okunade G.W., Miller M.L., Pyne G.J., Sutliff R.L., O'Connor K.T., Neumann J.C., et al. Targeted ablation of plasma membrane Ca2+-ATPase (PMCA)1 and 4 indicates a major housekeeping role in hyperactivated sperm motility and male fertility for PMCA4. J. Biol. Chem. 2004, 279:33742-33750.
42. Reuter H., Henderson S.A., Han T., Ross R.S., Goldhaber J.I., Philipson K.D. The Na2+-Ca2+ exchanger is essential for the action of cardiac glycosides. Circ. Res. 2002, 90:305-308.
43. Wakimoto K., Kobayashi K., Kuro O., Yao A., Iwamoto T., Yanaka N., et al. Targeted disruption of Na+/Ca2+ exchanger gene leads to cardiomyocyte apoptosis and defects in heartbeat. J. Biol. Chem. 2000, 275:36991-36998.
44. Bouillon R., Okamura W.H., Norman A.W. Structure-function relationships in the Vitamin D endocrine system. Endocr. Rev. 1995, 6:200-257.
45. Sutton A.L., MacDonald P.N. Vitamin D: more than a "bone-a-fide" hormone. Molec. Endocrinol. 2003, 17:777-791.
46. Brown E.M., MacLeod R.J. Extracellular calcium sensing and extracellular calcium signaling. Physiol. Rev. 2001, 81:239-297.
47. Hendy G.N., Guarnieri V., Canaff L. Calcium-sensing receptor and associated diseases. Prog. Mol. Biol. Transl. Sci. 2009, 89C:31-95.
48. Habener J.F., Rosenblatt M., Potts J.T. Parathyroid hormone: biochemical aspects of biosynthesis, secretion, action, and metabolism. Physiol. Rev. 1984, 64:985-1053.
49. Moallem E., Kilav R., Silver J., Naveh-Many T. RNA protein binding and post-transcriptional regulation of PTH gene expression by calcium and phosphate. J. Biol. Chem. 1998, 273:5253-5259.
50. Russell J., Silver J., Sherwood L.M. The effects of calcium and Vitamin D metabolites on cytoplasmic mRNA coding for pre-proparathyroid hormone in isolated parathyroid cells. Trans. Assoc. Am. Physicians. 1984, 97:296-303.
51. Kremer R., Bolivar I., Goltzman D., Hendy G.N. Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells. Endocrinology 1989, 125:935-941.
52. Meir T., Levi R., Lieben L., Libutti S., Carmeliet G., Bouillon R., et al. Deletion of the vitamin D receptor specifically in the parathyroid demonstrates a limited role for the receptor in parathyroid physiology. Am. J. Physiol. Renal. Physiol. 2009, 297:F1192-F1198.
53. Miao D., He B., Karaplis A.C., Goltzman D. Parathyroid hormone is essential for normal fetal bone formation. J. Clin. Invest. 2002, 109:1173-1182.
54. Miao D., He B., Lanske B., Bai X.-Y., Tong X.-K., Hendy G.N., et al. Chapter 13. Skeletal and reproductive abnormalities in PTH-null mice. Molecular Biology of the Parathyroid 2005, 179-196. Eurekah.com and Kluwer Academic/Plenum Publisher. T. Naveh-Many (Ed.).
55. Xue Y., Karaplis A.C., Hendy G.N., Goltzman D., Miao D. Genetic models show that parathyroid hormone and 1,25-dihydroxyvitamin D3 play distinct and synergistic roles in postnatal mineral ion homeostasis and skeletal development. Hum. Mol. Genet. 2005, 14:1515-1528.
56. Xue Y., Zhang Z., Karaplis A.C., Hendy G.N., Goltzman D., Miao D. Exogenous PTH-related protein and PTH improve mineral and skeletal status in 25-hydroxyvitamin D-1α-hydroxylase and PTH double knockout mice. J. Bone Miner. Res. 2005, 20:1766-1777.
57. Xue Y., Karaplis A.C., Hendy G.N., Goltzman D., Miao D. Exogenous 1,25-dihydroxyvitamin D3 exerts a skeletal anabolic effect and improves mineral ion homeostasis in mice that are homozygous for both the 1alpha-hydroxylase and parathyroid hormone null alleles. Endocrinology 2006, 147:4801-4810.
58. Tenenhouse H.S. Regulation of phosphorus homeostasis by the type IIa Na/phosphate cotransporter. Annu. Rev. Nutr. 2005, 25:197-214.
59. Bacic D., Lehir M., Biber J., Kaissling B., Murer H., Wagner C.A. The renal Na/phosphate cotransporter NaPi-IIa is internalized via the receptor-mediated endocytic route in response to parathyroid hormone. Kidney Int. 2006, 69:495-503.
60. Hattenhauer O., Traebert M., Murer H., Biber J. Regulation of small intestinal Na-P(i) type IIb cotransporter by dietary phosphate intake. Am. J. Physiol. 1999, 277:G756-G762.
61. Xu H., Bai L., Collins J.F., Ghishan F.K. Age-dependent regulation of rat intestinal type IIb sodium-phosphate cotransporter by 1,25-(OH)(2) vitamin D(3). Am. J. Physiol. Cell Physiol. 2002, 282:C487-C493.
62. Segawa H., Kaneko I., Yamanaka S., Ito M., Kuwahata M., Inoue Y., et al. Intestinal Na-P(i) cotransporter adaptation to dietary P(i) content in vitamin D receptor null mice. Am. J. Physiol. Renal. Physiol. 2004, 287:F39-F47.
63. Capuano P., Radanovic T., Wagner C.A., Bacic D., Kato S., Uchiyama Y., et al. Intestinal and renal adaptation to a low-Pi diet of type II NaPi cotransporters in vitamin D receptor and 1αOHase-deficient mice. Am. J. Physiol. Cell Physiol. 2005, 288:C429-C434.
64. Amling M., Priemel M., Holzmann T., Chapin K., Rueger J.M., Baron R., et al. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology 1999, 140:4982-4987.
65. Dardenne O., Prudhomme J., Hacking S.A., Glorieux F.H. Correction of the abnormal mineral ion homeostasis with a high-calcium, high-phosphorus, high-lactose diet rescues the PDDR phenotype of mice deficient for the 25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1). Bone 2003, 32:332-340.
66. Suda T., Ueno Y., Fujii K., Shinki T. Vitamin D and bone. J. Cell Biochem. 2003, 88:259-266.
67. Van Leeuwen J.P., van Driel M., van den Bernd G.J., Pols H.A. Vitamin D control of osteoblast function and bone extracellular matrix mineralization. Crit. Rev. Eukaryot. Gene Expr. 2001, 11:199-226.
68. Sabbagh Y., Carpenter T.O., Demay M.B. Hypophosphatemia leads to rickets by impairing caspase-mediated apoptosis of hypertrophic chondrocytes. Proc. Natl. Acad. Sci. USA 2005, 102:9637-9642.
69. Rowling M.J., Gliniak C., Welsh J., Fleet J.C. High dietary vitamin D prevents hypocalcemia and osteomalacia in CYP27B1 knockout mice. J. Nutr. 2007, 137:2608-2615.
70. Masuyama R., Stockmans I., Torrekens S., Van Looveren R., Maes C., Carmeliet P., et al. Vitamin receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J. Clin. Invest. 2006, 116:3150-3159.
71. 3 in growth plate development. Endocrinology 2009, 150:4024-4032.
72. Yagishita N., Yamamoto Y., Yoshizawa T., Sekine K., Uematsu Y., Murayama H., et al. Aberrant growth plate development in VDR/RXRγ double null mutant mice. Endocrinology 2001, 142:5332-5341.
73. Larsson T., Marsell R., Schipani E., Ohlsson C., Ljunggren O., Tenenhouse H.S., et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the α1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 2004, 145:3087-3094.
74. Shimada T., Haseqawa H., Yamazaki Y., Muto T., Hino R., Takeuchi Y., et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 2004, 19:429-435.
75. Ben Dov I.Z., Galitzer H., Lavi-Moshayoff V., Goetz R., Kuro O., Mohammadi M., et al. The parathyroid is a target organ for FGF23 in rats. J. Clin. Invest. 2007, 117:4003-4008.
76. Shimada T., Yamazaki Y., Takahashi M., Hasegawa H., Urakawa I., Oshima T., et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am. J. Physiol. Renal. Physiol. 2005, 289:F1088-F1095.
77. Inoue Y., Seqawa H., Kaneko I., Yamanaka S., Kusano K., Kawakami E., et al. Role of the vitamin D receptor in FGF23 action on phosphate metabolism. Biochem. J. 2005, 390:325-331.
78. Miyamoto K., Ito M., Kuwahata M., Kato S., Segawa H. Inhibition of intestinal sodium-dependent inorganic phosphate transport by fibroblast growth factor 23. Ther. Apher. Dial. 2005, 9:331-335.
79. Sitara D., Razzaque M.S., St.Arnaud R., Huang W., Taguchi T., Erben R.G., et al. Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-nul animals. Am. J. Pathol. 2006, 169:2161-2170.
80. Razzaque M.S., Sitara D., Taguchi T., St Arnaud R., Lanske B. Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB J. 2006, 20:720-722.
81. Hesse M., Frolich L.F., Zeitz U., Lanske B., Erben R.G. Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice. Matrix. Biol. 2007, 26:75-84.
82. Urakawa I., Yamazaki Y., Shimada T., Iijima K., Hasegawa H., Okawa K., et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006, 444:770-774.
83. Kuro-o M., Matsumara Y., Aizawa H., Kawaguchi H., Suga T., Utsugi T., et al. Mutation of the mouse Klotho gene leads to a syndrome resembling aging. Nature 1997, 390:45-51.
84. Razzaque M.S., Lanske B. Hypervitaminosis D and premature aging: lessons learned from Fgf23 and Klotho mutant mice. Trends Mol. Med. 2006, 12:298-305.
85. Tsujikawa H., Kurotaki Y., Fujimori T., Fukuda K., Nabeshima Y. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol. Endocrinol. 2003, 17:2393-2403.
86. Tenenhouse H.S., Gauthier C., Chau H., St Arnaud R. 1α-Hydroxylase gene ablation and Pi supplementation inhibit renal calcification in mice homozygous for the disrupted Npt2a gene. Am. J. Physiol. Renal. Physiol. 2004, 286:F675-F681.
87. 3 receptors: structure and function in transcription. Annu. Rev. Nutr. 1991, 11:189-216.
88. 3-regulated gene expression by microarray analysis. J. Steroid Biochem. Mol. Biol. 2004, 89-90:239-244.
89. Hewison M., Adams J.S. Chapter 79: Extra-renal 1α-hydroxylase activity and human disease. Vitamin D 2005, 1379-1402. Elsevier Academic Press, New York. second ed. D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
90. Teng M., Wolf M., Ofsthun M.N., Lazarus J.M., Hernán M.A., Carmargo C.A., et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J. Am. Soc. Nephrol. 2005, 16:1115-1125.
91. Autier P., Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch. Intern. Med. 2007, 167:1730-1737.
92. Yu S., Cantorna M.T. The vitamin D receptor is required for iNKT cell development. Proc. Natl. Acad. Sci. USA 2008, 105:5207-5212.
93. Zinser G.M., Suckow M., Welsh J. Vitamin D receptor (VDR) ablation alters carcinogen-induced tumorigenesis in mammary gland, epidermis and lymphoid tissues. J. Steroid Biochem. Mol. Biol. 2005, 97:153-164.
94. Zeitz U., Weber K., Soegiarto D.W., Wolf E., Balling R., Erben R.G. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J. 2003, 17:509-511.
95. Li Y.C., Kong J., Wei M., Chen Z.F., Liu S.Q., Cao L.P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest. 2002, 110:229-238.
96. Endo I., Inoue D., Mitsui T., Umaki Y., Akaike M., Yoshizawa T., et al. Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology 2003, 144:5138-5144.
97. Burne T.H., McGrath J.J., Eyles D.W., Mackay-Sim A. Behavioural characterization of vitamin D receptor knockout mice. Behav. Brain Res. 2005, 157:299-308.
98. W. Sun, H. Xie, J. Ji, X. Zhou, D. Goltzman, D. Miao, Defective female reproductive function in 1,25(OH)2D deficient mice results from an indirect effect mediated by extracellular calcium and/or phosphorus, Am. J. Physiol. - Endocrinol. Metab. In press.
99. Ruth Wu-Wong J., Nakane M., Ma J., Cook A.L. Vitamin D analogs down-regulate plasminogen activator inhibitor-1 in human coronary artery smooth muscle cells. J. Thromb. Haemost. 2005, 3:1545-1546.
100. Xiang W., Kong J., Chen S., Cao L.P., Qiao G., Zheng W., et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am. J. Physiol. Endocrinol. Metab. 2005, 288:E125-E132.
101. Zhou C., Lu F., Cao K., Xu D., Goltzman D., Miao D. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int. 2008, 74:170-179.
102. Kristal-Boneh E., Froom P., Harari G., Ribak J. Association of calcitriol and blood pressure in normotensive men. Hypertension 1997, 30:1289-1294.
103. Lind L., Hanni A., Lithell H., Hvarfner A., Sorensen O.H., Ljunghall S. Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am. J. Hypertens. 1995, 8:894-901.
104. Burgess E.D., Hawkins R.G., Watanabe M. Interaction of 1,25-dihydroxyvitamin D and plasma renin activity in high renin essential hypertension. Am. J. Hypertens. 1990, 3:903-905.
105. Lind L., Wengle B., Wide L., Ljunghall S. Reduction of blood pressure during long-term treatment with active vitamin D (alphacalcidol) is dependent on plasma renin activity and calcium status. A double-blind, placebo-controlled study. Am. J. Hypertens. 1989, 2:20-25.
106. Zhang Z., Sun L., Wang Y., Ning G., Minto A.W., Kong J., et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int. 2008, 73:163-171.
107. Agarwal R., Acharya M., Tian J., Hippensteel R.L., Melnick J.Z., Qiu P., et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005, 68:2823-2828.
108. Simpson R.U., Hershey S.H., Nibbelink K.A. Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J. Steroid Biochem. Mol. Biol. 2007, 103:521-524.
109. Tishkoff D.X., Nibbelink K.A., Holmberg K.H., Dandu L., Simpson R.U. Functional vitamin D receptor in the T-tubules of cardiac myocytes. Endocrinology 2008, 149:558-564.
110. Rahman A., Hershey S., Ahmed S., Nibbelink K., Simpson R.U. Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice. J. Steroid Biochem. Mol. Biol. 2007, 103:416-419.
111. Aihara K., Azuma H., Akaike M., Ikeda Y., Yamashita M., Sudo T., et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J. Biol. Chem. 2004, 279:35798-35802.
112. St Arnaud R. Targeted inactivation of vitamin D hydroxylases in mice. Bone 1999, 25:127-129.
113. Shimada T., Kakitani M., Yamazaki Y., Hasegawa H., Takeuchi Y., Fujita T., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 2004, 113:561-568.
114. Johnson R.C., Leopold J.A., Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. Circ. Res. 2006, 99:1044-1059.
115. Holick M.F. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am. J. Clin. Nutr. 2004, 80(Suppl. 6):S1678-S1688.
116. Grant W.B. Ecologic studies of solar UV-B radiation and cancer mortality rates. Recent Results Cancer Res. 2003, 164:371-377.
117. Goodwin P.J. Frequency of vitamin D (Vit D) deficiency at breast cancer (BC) diagnosis and association with risk of distant recurrence and death in a prospective cohort study of T1-3, N0-1, and M0 BC. Annual Meeting of the American Society of Clinical Oncology 2008, Toronto Abstract No. 511.
118. Garland F.C., Garland C.F., Gorham E.D., Young J.F. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev. Med. 1990, 19:614-622.
119. Grant W.B. An estimate of premature cancer mortality in the US because of inadequate doses of solar ultraviolet-B radiation. Cancer 2002, 94:1867-1875.
120. Garland C.F., Gorham E.D., Baggerly C.A., Garland F.C. Re: Prospective study of vitamin D and cancer mortality in the United States. J. Natl. Cancer Inst. 2008, 100:826-827.
121. Colston K.W., Berger U., Coombes R.C. Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet 1989, 1:188-191.
122. Holick M.F., Jenkins M. The UV Advantage 2003, iBooks, New York, NY.
123. Holick M.F. Photosynthesis of vitamin D in the skin: effect of environmental and life-style variables. Fed. Proc. 1987, 46:1876-1882.
124. Moore C.E., Murphy M.M., Holick M.F. Vitamin D intakes by children and adults in the United States differ among ethnic groups. J. Nutr. 2005, 135:2478-2485.
125. 3 modulation of mammary tumor cell growth in vitro and in vivo. Breast Cancer Res. Treat 2003, 27:69-81.
126. 3. Clin. Endocrinol. (Oxf.) 1983, 13:267-272.
127. James S.Y., Mackay A.G., Binderup L., Colston K.W. Effects of a new synthetic vitamin D analogue, EB 1089, on the estrogen responsive growth of human breast cancer cells. J. Endocrinol. 1994, 141:555-563.
128. Hansen C.M., Mäenpää P.H. EB 1089, a novel vitamin D analog with strong antiproliferative and differentiation-inducing effects on targets cells. Biochem. Pharmacol. 1997, 54:1173-1179.
129. 3 suppresses growth and induces differentiation in an autocrine fashion. Mol. Cancer Res. 2002, 1:56-67.
130. Holick M.F. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am. J. Clin. Nutr. 2004, 79:362-371.
131. Wu-Wong J.R., Tian J., Goltzman D. Vitamin D analogs as therapeutic agents: a clinical study update. Curr. Opin. Investig. Drugs 2004, 5:320-326.
132. 3 in a keratinocyte model of tumor progression. J. Biol. Chem. 1992, 267:12162-12167.
133. El Abdaimi K., Papavasiliou V., Rabbani S.A., Rhim J.S., Goltzman D., Kremer R. Reversal of hypercalcemia with the vitamin D analogue EB1089 in a human model of squamous cancer. Cancer Res. 1999, 59:3325-3328.
134. 3 and EB 1089 on cell cycle kinetics and apoptosis in MCF-7 cells. Breast Cancer Res. Treat. 1997, 42:31-41.
135. 3 on cell-cycle kinetics of T47D human breast cancer cells. J. Cell Physiol. 1989, 138:611-616.
136. 3. Proc. Natl. Acad. Sci. USA 1990, 87:369-373.
137. Haq M., Kremer R., Goltzman D., Rabbani S.A. A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo. J. Clin. Invest. 1993, 91:2416-2422.
138. 3 analogue MC903 on secretion of interleukin-1(IL-1) and IL-8 by normal human keratinocytes and a human squamous cell carcinoma cell line (HSC-1). J. Dermatol. Sci. 1994, 7:24-31.
139. Jensen S.S., Madsen M.W., Lukas J., Binderup L., Bartek J. Inhibitory effects of 1,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol. Endocrinol. 2001, 15:1370-1380.
140. Liu M., Lee M.H., Cohen M., Bommakanti M., Freedman L.P. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 1996, 10:142-153.
141. Wang Q.M., Jones J.B., Studzinski G.P. Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res. 1996, 56:264-267.
142. Verlinden L., Verstuyf A., Convents R., Marcelis S., Van Camp M., Bouillon R. Action of 1,25(OH)2D3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells. Mol. Cell. Endocrinol. 1998, 142:57-65.
143. Nakagawa K., Kawaura A., Kato S., Takeda E., Okano T. 1,25-Dihydroxyvitamin D(3) is a preventive factor in the metastasis of lung cancer. Carcinogenesis 2005, 26:429-440.
144. Majewski S., Skopinska M., Marczak M., Szmurlo A., Bollag W., Jablonska S. Vitamin D3 is a potent inhibitor of tumor cell induced angiogenesis. J. Investig. Dermatol. Symp. Proc. 1996, 1:97-101.
145. Flynn G., Chung I., Yu W.D., Romano M., Modzelewski R.A., Johnson C.S., et al. Calcitriol (1,25-dihydroxycholecalciferol) selectively inhibits proliferation of freshly isolated tumor-derived endothelial cells and induces apoptosis. Oncology 2006, 70:447-457.
146. Ben Shoshan M., Amir S., Dang D.T., Dang L.H., Weisman Y., Mabjeesh N.J. 1,25-Dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol. Cancer. Ther. 2007, 6:1433-1439.
147. Nakagawa K., Sasaki Y., Kato S., Kubodera N., Okano T. 22-Oxa-1,25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 2005, 26:1044-1054.
148. Nakagawa K., Kawaura A., Kato S., Takeda E., Okano T. Metastatic growth of lung cancer cells is extremely reduced in vitamin D receptor knockout mice. J. Steroid Biochem. Mol. Biol. 2004, 89-90:545-547.
149. Gonzalez-Sancho J.M., Alvarez-Dolado M., Munoz A. 1,25-Dihydroxyvitamin D3 inhibits tenascin-C expression in mammary epithelial cells. FEBS Lett. 1998, 426:225-228.
150. Zehnder D., Bland R., Williams M.C., McNinch R.W., Howie A.J., Stewart P.M., et al. Extra renal expression of 25-hydroxyvitamin D(3)-1 alpha-hydroxylase. J. Clin. Endocrinol. Metab. 2001, 86:888-894.
151. Schwartz G.G., Whitlatch L.W., Chen T.C., Lokeshwar B.L., Holick M.F. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol. Biomarkers Prev. 1998, 7:391-395.
152. Barreto A.M., Schwartz G.G., Woodruff R., Cramer S.D. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol. Biomarkers Prev. 2000, 9:265-270.
153. Lou Y.R., Laaksi I., Sylvala H., Blauer M., Tammera T.L.J., Ylikomi T., et al. 25-Hydroxyvitamin D3 is an active hormone in human primary prostatic stromal cells. FASEB J. 2004, 18:332-334.
154. Bland R., Markovic D., Hills C.E., Hughes S.V., Chan S.L., Squires P.E., et al. Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in pancreatic islets. J. Steroid Biochem. Mol. Biol. 2004, 89-90:121-125.
155. Eyles D.W., Smith S., Kinobe R., Hewison M., McGrath J.J. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J. Chem. Neuroanat. 2005, 29:21-30.
156. Segersten U., Kaae H.P., Björklund P., Hessman O., Nordgren H., Binderup L., Åkerström G., et al. 25-hydroxyvitamin D3 1α-hydroxylase expression in breast cancer and use of non-1α-hydroxylated vitamin D analogue. Breast Cancer Res. 2005, 7:980-986.
157. Townsend K., Evans K.N., Campbell M.J., Colston K.W., Adams J.S., Hewison M., et al. Biological actions of extra-renal 25-hydroxyvitamin D-1alpha-hydroxylase and implications for chemoprevention and treatment. J. Steroid Biochem. Mol. Biol. 2005, 97:103-109.
158. Christakos S., Dhawan P., Liu Y., Peng X., Porta A. New insights into the mechanisms of vitamin D action. J. Cell Biochem. 2003, 88:695-705.
159. Albertson D.G., Ylstra B., Segraves R., Collins C., Dairkee S.H., Kowbel D., et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat. Genet. 2000, 25:144-146.
160. Tangpricha V., Spina C., Yao M., Chen T.C., Wolfe M.M., Holick M.F., et al. Vitamin D deficiency enhances the growth of MC-26 colon cancer xenografts in Balb/c mice. J. Nutr. 2005, 135:2350-2354.
161. Zinser G.M., Sundberg J.P., Welsh J. Vitamin D(3) receptor ablation sensitizes skin to chemically induced tumorigenesis. Carcinogenesis 2002, 23:2103-2109.
162. Mordan-McCombs S., Brown T., Wang W.L., Gaupel A.C., Welsh J., Tenniswood M. Tumor progression in the LPB-Tag transgenic model of prostate cancer is altered by vitamin D receptor and serum testosterone status. J. Steroid Biochem. Mol. Biol. 2010, 121:368-371.
163. 3) 1α-hydroxylase in a human melanoma metastatic tumour cells enhances invasion in vitro and skeletal metastasis in vivo. J. Bone Miner. Res. 2006, 21s1:1100.
164. Lin E.Y., Jones J.G., Li P., Zhu L., Whitney K.D., Muller W.J., et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am. J. Pathol. 2003, 163:2113-2126.
165. Eash S., Manley K., Gasparovic M.L., Querbes W., Atwood W.J. The human polyomaviruses. Cell Mol. Life Sci. 2006, 63:865-876.
166. Gottlieb K.A., Villarreal L.P. Natural biology of polyomavirus middle T antigen. Microbiol. Mol. Biol. Rev. 2001, 65:288-318.
167. Bocchetta M., Carbone M. SV40-Mediated oncogenesis. Malignant Mesothelioma Advances in Pathogenesis, Diagnosis, and Translational Therapies 2000, Springer, New York, pp. 34-59.
168. Dawe C.J., Freund R., Mandel G., Ballmer-Hofer K., Talmage D.A., Benjamin T.L. Variations in polyomavirus genotype in relation to tumor induction in mice. Am. J. Pathol. 1987, 127:243-261.
169. Berebbi M., Dandolo L., Hassoun J., Bernard A.M., Blangy D. Specific tissue targeting of polyoma virus oncogenicity in athymic nude mice. Oncogene 1988, 2:149-156.
170. Haslam S.Z., Wirth J.J., Counterman L.J., Fluck M.M. Characterization of the mammary hyperplasia, dysplasia, and neoplasia induced in athymic female adult mice by polyomavirus. Oncogene 1992, 7:1295-1303.
171. Siegel P.M., Hardy W.R., Muller W.J. Mammary gland neoplasia: insights from transgenic mouse models. Bioessays 2000, 22:554-563.
172. Dankort D.L., Muller W.J. Signal transduction in mammary tumorigenesis: a transgenic perspective. Oncogene 2000, 19:1038-1044.
173. 3. ASBMR 30th. Ann. Meet 2008, Montreal, September 12-16.
174. 3-1α-hydroxylase gene (CYP27B1) in mammary epithelial cells accelerates breast cancer development in vitamin D sufficient PyVMT transgenic mice. ASBMR 31st Ann. Meet. Denver 2009.
175. Ma Y., Trump D.L., Johnson C.S. Vitamin D in combination cancer treatment. J. Cancer 2010, 1:101-107.
176. 2D: interacting drivers of epidermal differentiation. J. Steroid Biochem. Mol. Biol. 2004, 89-90:355-360.
177. Bikle D.D. Vitamin D regulated keratinocyte differentiation. J. Cell Biochem. 2004, 92:436-444.
178. Xie Z., Komuves L., Yu Q.C., Elalieh H., Ng D.C., Leary C., et al. Lack of the vitamin D receptor is associated with reduced epidermal differentiation and hair follicle growth. J. Invest. Dermatol. 2002, 118:11-16.
179. Sakai Y., Demay M.B. Evaluation of keratinocyte proliferation and differentiation in vitamin D receptor knockout mice. Endocrinology 2000, 141:2043-2049.
180. Malloy P.J., Pike J.W., Feldman D. The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets. Endocr. Rev. 1999, 20:156-188.
181. Sakai Y., Kishimoto J., Demay M.B. Metabolic and cellular analysis of alopecia in vitamin D receptor knockout mice. J. Clin. Invest. 2001, 107:961-966.
182. Chen C.H., Sakai Y., Demay M.B. Targeting expression of the human vitamin D receptor to the keratinocytes of vitamin D receptor null mice prevents alopecia. Endocrinology 2001, 142:5386-5389.
183. Kong J., Li X.J., Gavin D., Jiang Y., Li Y.C. Targeted expression of human vitamin D receptor in the skin promotes the initiation of the postnatal hair follicle cycle and rescues the alopecia in vitamin D receptor null mice. J. Invest. Dermatol. 2002, 118:631-638.
184. Skorija K., Cox M., Sisk J.M., Dowd D.R., MacDonald P.N., Thompson C.C., et al. Ligand-independent actions of the vitamin D receptor maintain hair follicle homeostasis. Mol. Endocrinol. 2005, 19:855-862.
185. Miller J., Djabali K., Chen T., Liu Y., Ioffreda M., Lyle S., et al. Atrichia caused by mutations in the vitamin D receptor gene is a phenocopy of generalized atrichia caused by mutations in the hairless gene. J. Invest. Dermatol. 2001, 117:612-617.
186. Hsieh J.C., Sisk J.M., Jurutka P.W., Haussler C.A., Slater S.A., Haussler M.R., et al. Physical and functional interaction between the vitamin D receptor and hairless corepressor, two proteins required for hair cycling. J. Biol. Chem. 2003, 278:38665-38674.
187. Xie Z., Chang S., Oda Y., Bikle D.D. Hairless suppresses vitamin D receptor transactivation in human keratinocytes. Endocrinology 2006, 147:314-323.
188. Merrill B.J., Gat U., DasGupta R., Fuchs E. Tcf3 and Lef1 regulate lineage differentiation of multipotential stem cells in skin. Genes Dev. 2001, 15:1688-1705.
189. Cianferroti L., Cox M., Skorija K., Demay M.B. Vitamin D receptor is essential for normal keratinocyte stem cell function. Proc. Natl. Acad. Sci. USA 2007, 104:9428-9433.
190. Bikle D.D., Chang S., Crumtine D., Elalieh H., Man M.Q., Choi E.H., et al. 25-Hydroxyvitamin D-1α-hydroxylase is required for optimal epidermal differentiation and permeability homeostasis. J. Invest. Dermatol. 2004, 122:984-992.
191. Hewison M., Burke F., Evans K.N., Lammas D.A., Sansom D.M., Liu P., et al. Extra-renal 25-hydroxyvitamin D3-1-hydroxylase in human health and disease. J. Steroid Biochem. Mol. Biol. 2007, 103:316-321.
192. Veldman C.M., Cantorna M.T., DeLuca H.F. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch. Biochem. Biophys. 2000, 374:334-338.
193. Laureys J., Rutgeerts O., Saint-Arnaud R., Bouillon R., Mathieu C. Identification and immune regulation of 25-hydroxyvitamin D-1-α-hydroxylase in murine macrophages. Clin. Exp. Immunol. 2000, 120:139-146.
194. Dusso A.S., Kamimura S., Gallieni M., Zhong M., Negrea L., Shapiro S., et al. γ-Interferon-induced resistance to 1,25-(OH)2D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses. J. Clin. Endocrinol. Metab. 1997, 82:2222-2232.
195. Stoffels K., Overbergh L., Giulietti A., Verlinden L., Bouillon R., Mathieu C. Immune regulation of 25-hydroxyvitamin-D3-1-hydroxylase in human monocytes. J. Bone Miner. Res. 2006, 21:37-47.
196. Vidal M., Ramana C.V., Dusso A.S. Stat1-vitamin D receptor interactions antagonize 1,25-dihydroxyvitamin D transcriptional activity and enhance stat1-mediated transcription. Mol. Cell Biol. 2002, 22:2777-2787.
197. Yu X.P., Bellido T., Manolagas S.C. Down-regulation of NF-B protein levels in activated human lymphocytes by 1,25-dihydroxyvitamin D3. Proc. Natl. Acad. Sci. USA 1995, 92:10990-10994.
198. Bouillon R., Carmeliet G., Verlinden L., van Etten E., Verstuyf A., Luderer H.F., et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr. Rev. 2008, 29:726-776.
199. Lim W.C., Hanauer S.B., Li Y.C. Mechanisms of disease: vitamin D and inflammatory bowel disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2005, 2:308-315.
200. Cutolo M., Otsa K., Uprus M., Paolino S., Seriolo B. Vitamin D in rheumatoid arthritis. Autoimmun. Rev. 2007, 7:59-64.
201. Kamen D.L., Cooper G.S., Bouali H., Shaftman S.R., Hollis B.W., Gilkeson G.S. Vitamin D deficiency in systemic lupus erythematosus. Autoimmun. Rev. 2006, 5:114-117.
202. Munger K.L., Levin L.I., Hollis B.W., Howard N.S., Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296:2832-2838.
203. Hypponen E., Laara E., Reunanen A., Jarvelin M.R., Virtanen S.M. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001, 358:1500-1503.
204. O'Kelly J., Hisatake J., Hisatake Y., Bishop J., Norman A., Koeffler H.P. Normal myelopoiesis but abnormal T lymphocyte responses in vitamin D receptor knockout mice. J. Clin. Invest. 2002, 109:1091-1099.
205. Baroni E., Biffi M., Benigni F., Monno A., Carlucci D., Carmeliet G., et al. VDR-dependent regulation of mast cell maturation mediated by 1,25-dihydroxyvitamin D3. J. Leukoc. Biol. 2007, 81:250-262.
206. Froicu M., Cantorna M.T. Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. BMC Immunol. 2007, 8:5.
207. Meehan T.F., DeLuca H.F. The vitamin D receptor is necessary for 1,25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. Arch. Biochem. Biophys. 2002, 408:200-204.
208. Cantorna M.T., Hayes C.E., DeLuca H.F. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc. Natl. Acad. Sci. USA 1996, 93:7861-7864.
209. Spach K.M., Hayes C.E. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J. Immunol. 2005, 175:4119-4126.
210. Zella J.B., DeLuca H.F. Vitamin D and autoimmune diabetes. J. Cell Biochem. 2003, 88:216-222.
211. Mathieu C., Waer M., Casteels K., Laureys J., Bouillon R. Prevention of type I diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25-dihydroxyvitamin D3, KH1060. Endocrinology 1995, 136:866-872.
212. Wittke A., Chang A., Froicu M., Harandi O.F., Weaver V., August A., et al. Vitamin D receptor expression by the lung micro-environment is required for maximal induction of lung inflammation. Arch. Biochem. Biophys. 2007, 460:306-313.
213. Ehrchen J., Helming L., Varga G., Pasche B., Loser K., Gunzer M., et al. Vitamin D receptor signaling contributes to susceptibility to infection with Leishmania major. FASEB J. 2007, 21:3208-3218.
214. Gombart A.F., Borregaard N., Koeffler H.P. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J. 2005, 19:1067-1077.
215. Liu P.T., Stenger S., Li H., Wenzel L., Tan B.H., Krutzik S.R., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311:1770-1773.
216. Gregori S., Casorati M., Amuchastegui S., Smiroldo S., Davalli A.M., Adorini L. Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J. Immunol. 2001, 167:1945-1953.
217. Hewison M. Vitamin D and the immune system: new perspectives on an old theme. Endocrinol. Metab. Clin. North. Am. 2010, 39:365-379.
218. Hendy G.N., Goltzman D. Does calcitriol have actions independent from the vitamin D receptor in maintaining skeletal and mineral homeostasis? 2005, 14:350-354.